Video

Patients With Intermediate Stage HCC Unsuitable for TACE

Author(s):

Michael A. Morse, MD,Nicole Rich, MD

Expert panelists discuss treatment strategies for patients with intermediate stage hepatocellular carcinoma (HCC) that are unsuitable for transarterial chemoembolization (TACE).

Related Videos
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
5 KOLs are featured in this series.
Related Content
The OncFive: Top Oncology Articles for the Week of 11/17
November 23rd 2024

The OncFive: Top Oncology Articles for the Week of 11/17

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

FDA
November 21st 2024

FDA Approves Zanidatamab for Previously Treated, Unresectable or Metastatic HER2+ Biliary Tract Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Tanios S. Bekaii-Saab, MD
November 19th 2024

Liquid Biopsies, ctDNA Could Help Guide Gastrointestinal Cancer Management

Cindy M. Pabon, MD
November 18th 2024

Zolbetuximab Approval Paves Way for Precision Medicine in Gastric and GEJ Adenocarcinoma